SAN DIEGO, California, November 12, 2015 /PRNewswire/ --
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the initiation of preclinical studies evaluating utilization of NR2F6 gene silencing as a means of stimulating the immune system in cancer patients with Dr. Santosh Kesari, Professor of Neurosciences, Director of Neuro-Oncology, and Chair of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute. The studies will examine whether initial observations in mouse immune cells that NR2F6 silencing can be translated into human immune cells. If successful, these studies will serve as the basis for a new cancer immunotherapeutic drug candidate, which would be useful as a monotherapy or adjuvant with other cancer immune therapies.
"We have previously filed patents and to date have been granted allowance on one, covering compositions of matter capable of silencing NR2F6, means of screening drugs that modulate NR2F6, and various biological activities of this gene. Additionally, we have previously been successful at developing a clinical candidate, dCellVax, which is currently in front of the FDA, as a means of treating cancer. The current program seeks to leverage our existing know-how and intellectual property in order to develop a simple drug candidate applicable to numerous cancers," said Harry Lander, Ph.D., MBA, President of Regen BioPharma. "We are highly enthusiastic about working with Dr. Kesari, a well respected researcher and oncologist in cancer immunotherapy to mature this technology out of the laboratory and into the clinic."
Regen's dCellVax product involves extraction of blood from cancer patients, generating immune stimulatory cells termed dendritic cells, silencing an immune suppressive gene in the cells outside of the body, and subsequently administering these cells to the same patient. In the new program, Regen is performing essentially the same process but in T cells of the patient, and using our proprietary NR2F6 gene silencing technology.
"The immune system has two arms, the innate, and the adaptive, both of which have been demonstrated to contribute to killing of tumors," said Dr. Kesari. "While dCellVax operates at the level of the innate immune system, the NR2F6 program aims at directly stimulating the adaptive immune system at killing cancer. By initiating these experiments, we hope to offer diversity and potentially synergistic therapies for cancer patients."
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
SOURCE Regen BioPharma Inc.